コルチキンは,PIM2を標的とし,NF-κB信号経路を調節することによって,糖尿病と併合した動脈硬化症を緩和する.
PubMedで要約を見る
まとめ
この要約は機械生成です。コルキシンは,炎症を軽減し,PIM2タンパク質を標的として,糖尿病のマウスの動脈硬化症を効果的に治療します. この抗炎症薬は,糖尿病患者の冠動脈疾患 (CHD) の管理に有望である.
科学分野
- 薬理学について
- 心血管医学
- 免疫学
背景
- 冠動脈疾患 (CHD) の罹患率は世界的に増加しており,糖尿病 (DM) によって悪化しています.
- 動脈硬化に対する既存の治療法では,DMに関連する悪化を完全に対処することはできません.
- 抗炎症剤であるコルキシンは,心臓病の可能性を示していますが,さらなる調査が必要です.
研究 の 目的
- DMによる動脈硬化症の治療におけるコルキシンの効果とメカニズムを調査する.
- ネットワーク薬理学と実験モデルを通して発見を検証する.
主な方法
- 生物情報学データベース (GeneCard,OMIM,DisGeNET,DGIDB,Swiss Target Prediction) を用いて病気と薬物の標的を特定した.
- ゲノムオントロジー (GO) と基因とゲノムの京都百科事典 (KEGG) の濃縮分析を行った.
- トランスクリプトームシーケンス,分子ドッキング,分子動力学,表面プラズモン共鳴 (SPR),STZ誘発糖尿病性動脈硬化マウスモデル (APOE-/-) を利用した.
主要な成果
- 主に炎症および免疫経路 (MAPK,Jak-STAT,NF-κB) に関する140の潜在的な標的が特定されました.
- 4つの主要なマクロファージ標的 (PIM2,SIGLEC1,ANPEP,MAPK10) が発見され,特にPIM2に強く結合している.
- コルキシンは動脈硬化性プラークの領域,マクロファージの蓄積,および炎症マーカー (IL- 1β,IL- 6) をインビヴォおよびインビトロで減少させ,PIM2を主要標的として検証した.
結論
- コルチキンは,糖尿病患者の動脈硬化症に対する抗炎症療法としての可能性を示しています.
- このメカニズムは,マクロファージの機能を調節し,炎症経路を抑制するためにPIM2を標的とする.
関連する概念動画
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

